Several analysts have recently updated their ratings and price targets for Sarepta Therapeutics (NASDAQ: SRPT): 5/3/2016 – Sarepta Therapeutics was downgraded by analysts at Vetr from a “strong-buy” rating to a “hold” rating. They now have a $17.87 price target on the stock. 5/2/2016 – Sarepta Therapeutics was upgraded by analysts at Oppenheimer from a […]
